Tags

Type your tag names separated by a space and hit enter

[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
Ugeskr Laeger. 2011 Feb 21; 173(8):564-7.UL

Abstract

In eight studies included in the present Cochrane review the effects of orlistat or sibutramine versus placebo on mortality, cardiovascular mortality and adverse events were investigated in obese people with hypertension. No studies with rimonabant fulfilled the inclusion criteria. The weight loss was larger in the groups treated with orlistat or sibutramine compared with placebo therapy. Orlistat reduced systolic and diastolic blood pressure more than placebo, while blood pressure increased during treatment with sibutramine. The studies were too small and of too short duration to allow an evaluation of the effect on cardiovascular mortality and morbidity.

Authors+Show Affiliations

Endokrinologisk Afdeling, Hvidovre Hospital, Hvidovre, Denmark. sten.madsbad@hvh.regionh.dk

Pub Type(s)

Journal Article

Language

dan

PubMed ID

21333255

Citation

Madsbad, Sten. "[Long-term Effects of Weight-reducing Drugs in Hypertensive Patients--a Survey of a Cochrane Review]." Ugeskrift for Laeger, vol. 173, no. 8, 2011, pp. 564-7.
Madsbad S. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. Ugeskr Laeger. 2011;173(8):564-7.
Madsbad, S. (2011). [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. Ugeskrift for Laeger, 173(8), 564-7.
Madsbad S. [Long-term Effects of Weight-reducing Drugs in Hypertensive Patients--a Survey of a Cochrane Review]. Ugeskr Laeger. 2011 Feb 21;173(8):564-7. PubMed PMID: 21333255.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. A1 - Madsbad,Sten, PY - 2011/2/22/entrez PY - 2011/2/22/pubmed PY - 2011/3/26/medline SP - 564 EP - 7 JF - Ugeskrift for laeger JO - Ugeskr Laeger VL - 173 IS - 8 N2 - In eight studies included in the present Cochrane review the effects of orlistat or sibutramine versus placebo on mortality, cardiovascular mortality and adverse events were investigated in obese people with hypertension. No studies with rimonabant fulfilled the inclusion criteria. The weight loss was larger in the groups treated with orlistat or sibutramine compared with placebo therapy. Orlistat reduced systolic and diastolic blood pressure more than placebo, while blood pressure increased during treatment with sibutramine. The studies were too small and of too short duration to allow an evaluation of the effect on cardiovascular mortality and morbidity. SN - 1603-6824 UR - https://www.unboundmedicine.com/medline/citation/21333255/[Long_term_effects_of_weight_reducing_drugs_in_hypertensive_patients__a_survey_of_a_Cochrane_review]_ L2 - https://medlineplus.gov/obesity.html DB - PRIME DP - Unbound Medicine ER -